Skip to content

Effects of the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine on phencyclidine-induced behavior and expression of the immediate-early genes in the discrete brain regions of rats.

Leo Gotoh, Noriko Kawanami, Tatsuo Nakahara, Hisao Hondo, Keisuke Motomura, Eiko Ohta, Izumi Kanchiku, Toshihide Kuroki, Makoto Hirano, Hideyuki Uchimura

Brain research. Molecular brain research April 30, 2002 DOI: 10.1016/s0169-328x(02)00136-5 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical animal study Peer reviewed
Population Rats
Interventions N(6)-cyclopentyladenosine (CPA) phencyclidine (PCP)
Dose CPA 0.5 mg/kg, s.c.; PCP 7.5 mg/kg, s.c.
Measures locomotor activity, head weaving, mRNA levels of arc, c-fos, and jun B
Key points The selective adenosine A(1) receptor agonist CPA (0.5 mg/kg) significantly attenuated PCP-induced hyperlocomotion and head weaving, and reduced PCP-induced increases in c-fos mRNA in the medial prefrontal cortex and nucleus accumbens and arc expression in the medial prefrontal cortex and posterior cingulate cortex. The authors conclude these results provide further evidence for a significant antipsychotic effect of adenosine A(1) receptor agonists.

Abstract

Because of the possible interaction between adenosine receptors and dopaminergic functions, the compound acting on the specific adenosine receptor subtype may be a candidate for novel antipsychotic drugs. To elucidate the antipsychotic potential of the selective adenosine A(1) receptor agonist N(6)-cyclopentyladenosine (CPA), we examined herein the effects of CPA on phencyclidine (PCP)-induced behavior and expression of the immediate-early genes (IEGs), arc, c-fos and jun B, in the discrete brain regions of rats. PCP (7.5 mg/kg, s.c.) increased locomotor activity and head weaving in rats and this effect was significantly attenuated by pretreatment with CPA (0.5 mg/kg, s.c.). PCP increased the mRNA levels of c-fos and jun B in the medial prefrontal cortex, nucleus accumbens and posterior cingulate cortex, while leaving the striatum and hippocampus unaffected. CPA pretreatment significantly attenuated the PCP-induced increase in c-fos mRNA levels in the medial prefrontal cortex and nucleus accumbens. CPA also significantly attenuated the PCP-induced arc expression in the medial prefrontal cortex and posterior cingulate cortex. When administered alone, CPA decreased the mRNA levels of all IEGs examined in the nucleus accumbens, but not in other brain regions. Based on the ability of CPA to inhibit PCP-induced hyperlocomotion and its interaction with neural systems in the medial prefrontal cortex, posterior cingulate cortex and nucleus accumbens, the present results provide further evidence for a significant antipsychotic effect of the adenosine A(1) receptor agonist.

Citations in the library